Teva inhaler approved; Oxford to create center for drug delivery devices;

> Teva ($TEVA) received FDA approval for its Qvar inhaler with a dose counter to treat asthma. Release

> Oxford University announced plans for a new research center, The Oxford Centre for Drug Delivery Devices. Release

> Equashield announced FDA clearance of its eponymous first and second generation closed systems to minimize exposure to hazardous drugs. Release

> FDA agreed to review Mallinckrodt's ($MNK) New Drug Application for its extended-release oral formulation of hydrocodone and acetaminophen for pain management. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.